149 related articles for article (PubMed ID: 24462696)
1. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance.
Guan Y; Sun H; Li Y; Pan P; Li D; Hou T
Antiviral Res; 2014 Mar; 103():60-70. PubMed ID: 24462696
[TBL] [Abstract][Full Text] [Related]
2. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
Xue W; Wang M; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
[TBL] [Abstract][Full Text] [Related]
3. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
4. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
5. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.
Nagpal N; Goyal S; Wahi D; Jain R; Jamal S; Singh A; Rana P; Grover A
Gene; 2015 Oct; 570(1):115-21. PubMed ID: 26055089
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
Xue W; Pan D; Yang Y; Liu H; Yao X
Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.
Romano KP; Ali A; Royer WE; Schiffer CA
Proc Natl Acad Sci U S A; 2010 Dec; 107(49):20986-91. PubMed ID: 21084633
[TBL] [Abstract][Full Text] [Related]
8. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
9. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
10. Structural modeling of HCV NS3/4A serine protease drug-resistance mutations using end-point continuum solvation and side-chain flexibility calculations.
Hotiana HA; Haider MK
J Chem Inf Model; 2013 Feb; 53(2):435-51. PubMed ID: 23305404
[TBL] [Abstract][Full Text] [Related]
11. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.
Dultz G; Shimakami T; Schneider M; Murai K; Yamane D; Marion A; Zeitler TM; Stross C; Grimm C; Richter RM; Bäumer K; Yi M; Biondi RM; Zeuzem S; Tampé R; Antes I; Lange CM; Welsch C
J Biol Chem; 2020 Oct; 295(40):13862-13874. PubMed ID: 32747444
[TBL] [Abstract][Full Text] [Related]
12. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations.
Guan Y; Sun H; Pan P; Li Y; Li D; Hou T
Mol Biosyst; 2015 Sep; 11(9):2568-78. PubMed ID: 26219385
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V.
Ortqvist P; Vema A; Ehrenberg AE; Dahl G; Rönn R; Akerblom E; Karlén A; Danielson UH; Sandström A
Antivir Ther; 2010; 15(6):841-52. PubMed ID: 20834096
[TBL] [Abstract][Full Text] [Related]
14. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
[TBL] [Abstract][Full Text] [Related]
15. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.
Meeprasert A; Rungrotmongkol T; Li MS; Hannongbua S
Curr Pharm Des; 2014; 20(21):3465-77. PubMed ID: 24001230
[TBL] [Abstract][Full Text] [Related]
16. Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
Wang H; Geng L; Chen BZ; Ji M
Biochem Cell Biol; 2014 Oct; 92(5):357-69. PubMed ID: 25178998
[TBL] [Abstract][Full Text] [Related]
17. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic role of NS4A and substrate in the activation of HCV NS3 protease.
Zhu H; Briggs JM
Proteins; 2011 Aug; 79(8):2428-43. PubMed ID: 21633972
[TBL] [Abstract][Full Text] [Related]
19. Characterization of resistance mutations against HCV ketoamide protease inhibitors.
Tong X; Bogen S; Chase R; Girijavallabhan V; Guo Z; Njoroge FG; Prongay A; Saksena A; Skelton A; Xia E; Ralston R
Antiviral Res; 2008 Mar; 77(3):177-85. PubMed ID: 18201776
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
